Evidence map›Paper›PMID 33462515›Full record

ArticleNature metabolism2021

Tetracyclines promote survival and fitness in mitochondrial disease models.

Elizabeth A Perry, Christopher F Bennett, Chi Luo, Eduardo Balsa, Mark Jedrychowski, Katherine E O'Malley, Pedro Latorre-Muro, Richard Porter Ladley, Kamar Reda, Peter M Wright and 3 more

Open access · bronzeAbstract readLetter
In one paragraph

Article in Nature metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Advances in Management of Mitochondrial Myopathies.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The Blood-Brain Barrier Is Unaffected in theInternational journal of molecular sciences · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Elizabeth A Perry *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Christopher F Bennett *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1927-0732
Chi LuoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eduardo BalsaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mark JedrychowskiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Katherine E O'MalleyDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pedro Latorre-MuroDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6794-3535
Richard Porter LadleyDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3902-8292
Kamar RedaDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
Peter M WrightDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7626-0034
Andrew G MyersDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
Pere PuigserverDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. pere_puigserver@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-0884-2718
Harvard University · US

Funding

Insulin Signaling and Metabolic Effects through CLK2 KinaseR01DK089883 · NIDDK · DANA-FARBER CANCER INST · PI PUIGSERVER, PERE · 2011 to 2020
$3.8M
Metabolic and Bioenergetic Control in Mitochondrial DiseasesR01GM121452 · NIGMS · DANA-FARBER CANCER INST · PI PUIGSERVER, PERE · 2017 to 2020
$1.5M
Chemical Approaches to Rescue Human Mitochondrial Disease MutationsF30DE028206 · NIDCR · HARVARD MEDICAL SCHOOL · PI PERRY, ELIZABETH AGUILAR · 2018 to 2022
$190k
Characterization of genetic modifiers of bioenergetic rescue in mitochondrial disease cell linesF32GM125243 · NIGMS · DANA-FARBER CANCER INST · PI BENNETT, CHRISTOPHER F. · 2017 to 2020
$188k
NIDCR NIH HHS F30 DE028206NIDDK NIH HHS R01 DK089883NIGMS NIH HHS F32 GM125243NIGMS NIH HHS R01 GM121452
6 · The paper itself

Abstract

Mitochondrial diseases (MDs) are a heterogeneous group of disorders resulting from mutations in nuclear or mitochondrial DNA genes encoding mitochondrial proteins

Indexed as

Activating Transcription Factor 4AnimalsAnti-Bacterial AgentsBrainCells, CulturedDisease Models, AnimalElectron Transport Complex IHigh-Throughput Screening AssaysHumansLeigh DiseaseLife ExpectancyMetabolomicsMiceMice, KnockoutMitochondrial DiseasesPhysical FitnessActivating Transcription Factor 4Anti-Bacterial AgentsAtf4 protein, mouseElectron Transport Complex INdufs4 protein, mouseTetracyclines

Identifiers

PMID33462515
PMCPMC7856165
OpenAlexW3122386171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.